The stapled peptides of the present invention, and pharmaceutically acceptable salts thereof, are co-agonists of the glucagon and GLP-1 receptors, and may be useful in the treatment, prevention and suppression of diseases mediated by the glucagon receptor and the GLP-1 receptor, including but not limited to, metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.

The present invention relates to the photoredox-mediated functionalization of proteins with chemical groups via radical generated C—C bond formation, by using specific boronate and sulfone precursor compounds. The present invention also relates to functionalized proteins that can be generated via this method and to the specific boronate and sulfone precursor compounds themselves.

The present invention relates to a method for determining the presence or level of an analyte of interest and the use thereof. Further, present invention relates to an analytical system, a sampling tube and the use of the sampling tube and a nucleophilic derivatization reagent.

Processes for preparing compounds of Formula (1) and Formula (2) are described, wherein X, Y, Z, R.sub.1-R.sub.7, L and n are defined herein. Intermediates useful in the preparation of the compounds of Formula (1) and Formula (2) are also described. ##STR00001##

The invention relates to hybrid supported lipid bilayer (HSLB) including a phospholipid; a copolymer; and a membrane protein, wherein the membrane protein is functional, properly oriented within the lipid bilayer, and mobile within the lipid bilayer.

The present disclosure relates to methods of modifying phosphorylated or sulfated tyrosine residues of polypeptides or proteins. Benefits of the methods disclosed herein can include the specific modification of phosphorylated or sulfated tyrosine residues, and the identification, characterization and enrichment of tyrosine phosphorylated or sulfated peptides or proteins in complex biological mixtures.

This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.

The present invention relates to a facile acylation process for preparation of N-Substituted peptide and proteins. More specifically, the invention relates to acylating a peptide or a protein with deprotected acylating agent.

Doxorubicin derivatives for targeted activation by Legumain, its preparation method and use. The doxorubicin derivatives are obtained by condensation between the amino group of compound A and the carboxyl group of compound B and have the following structure: ##STR00001##
compounds A and B have the following structures, respectively: ##STR00002##
wherein R.sub.3 in compound B is Leu or absent; R.sub.4 is any one amino acid selected from the group consisting of Ala and Thr; R.sub.5 is any one amino acid selected from the group consisting of Ala, Thr and Asn; R.sub.6 is ##STR00003##
wherein n=1-20; or ##STR00004##
wherein R.sub.7 is substituted or unsubstituted, linear or branched, saturated or unsaturated C1-C20 fatty hydrocarbon, or substituted or unsubstituted C6-C20 aromatic hydrocarbon. The doxorubicin derivatives of the present invention are specifically tumor-targeted and have a long in vivo metabolic half-life, as compared with doxorubicin. They exhibit an efficient and safe anti-tumor effect and could be used to prepare an anti-tumor drug.

A molecular structure comprising a targeting moiety, a multi-functional peptide platform and a plurality of controllably released bioactive agents attached thereto is provided herein.